Pseudomonas aeruginosa virulence factors and surface antigens

Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen that utilizes a diverse array of virulence factors and surface antigens to establish infections, particularly in immunocompromised individuals and patients with cystic fibrosis [1]. These factors include structural components such as lipopolysaccharides (LPS), flagella, and type IV pili, which mediate attachment and motility, as well as secreted toxins like Exotoxin A and proteases that cause direct tissue damage [1, 5]. A key feature of P. aeruginosa pathogenesis is the Type III secretion system (T3SS), which injects effector proteins directly into host cells to subvert immune responses [2]. Additionally, the production of extracellular polysaccharides like alginate, Psl, and Pel facilitates the formation of robust biofilms, providing a physical barrier against antibiotics and phagocytosis [3]. Therapeutic approaches targeting these components, such as monoclonal antibodies like MEDI3902, aim to neutralize toxicity or enhance bacterial clearance, offering an alternative or adjunct to traditional antibiotic therapy [4]. These anti-virulence strategies offer a potential alternative to traditional antibiotics by disarming the pathogen without exerting strong selective pressure for resistance [4]. However, the high genetic diversity and redundancy of virulence factors among clinical isolates remain significant challenges for drug development [1]. Sources: [1] Gellatly & Hancock (2013) Pathog Dis; [2] Hauser (2009) Nat Rev Microbiol; [3] Ghafoor et al. (2011) J Bacteriol; [4] DiGiandomenico et al. (2014) Sci Transl Med; [5] Pier (2007) Nat Rev Microbiol.

Other names

Pseudomonas aeruginosa antigensP. aeruginosa virulence determinantsPseudomonas pathogenicity factorsPseudomonas surface antigens

Neutralization of virulence factors (e.g., PcrV, Exotoxin A), inhibition of bacterial adhesion and biofilm formation (e.g., via Psl/Pel targeting), and enhancement of opsonophagocytic killing (OPK) to facilitate immune-mediated clearance.